Please assess the completion status of the following clinical trial:

Trial Title: Clinical Utility of Endothelial Dysfunction in PAD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female subjects age 21-99 years old.~2. Peripheral Arterial Disease. PAD is defined clinically and by angiography, magnetic resonance imaging, vascular ultrasound, or ankle brachial index less than 0.9.~3. Able to provide informed consent and complete the study procedure.~4. Patients undergoing non-emergent vascular surgery (peripheral arterial bypass, abdominal aortic aneurysm repair, carotid endarterectomy, or limb amputation) or other non-cardiac surgery.~Exclusion Criteria:~1. Emergent or urgent surgery that must be performed sooner than one week after enrollment~2. Unstable angina, myocardial infarction, stroke, coronary revascularization, or decompensated heart failure within 1 month of enrollment. Patients who require cardiac catheterization and surgical or percutaneous coronary revascularization prior to vascular surgery will be excluded.~3. Clinically evident major illness of other organ systems, including cancer, end-stage renal disease, hepatic failure, or other conditions that make participation inappropriate.~4. Women who are lactating, pregnant, or of childbearing potential and not using a reliable contraceptive method. Pregnancy will be excluded by a urine pregnancy test.~5. Patients with liver function tests or serum creatine kinase \>3 times the upper limit of normal.~6. Patients who have received an investigational drug within 30 days of enrollment.~7. Patients or subjects with a history of a psychological illness or condition such as to interfere with the subject's ability to understand the requirements of the study.~8. Known occlusive atherosclerosis of the subclavian artery or upper extremity, because such disease will interfere with induction of reactive hyperemia during the brachial artery ultrasound studies.~9. Patients will be excluded if they are taking vitamin C in a dose greater than 2 times the Recommended Daily Allowance (\>120 mg/day) within 1 month of enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Atorvastatin (Type: EXPERIMENTAL): Atorvastatin 40 or 80 mg/day
- Ascorbic Acid (Type: EXPERIMENTAL): Ascorbic Acid 500 mg/day
- Placebo (Type: PLACEBO_COMPARATOR): Placebo atorvastatin and Placebo ascorbic acid

Based on this trial design, predict the completion outcome and termination type (if applicable).